

Title	Progress in understanding of the molecular basis underlying functional diversification of cyclic di-nucleotide turnover proteins
Author(s)	Römling, Ute; Liang, Zhao-Xun; Dow, J. Maxwell
Publication date	2016-12-18
Original citation	Römling, U., Liang, Z.-X. and Dow, J. M. (2016) 'Progress in understanding of the molecular basis underlying functional diversification of cyclic di-nucleotide turnover proteins', Journal of Bacteriology. Article in Press. doi:10.1128/jb.00790-16
Type of publication	Article (peer-reviewed)
Link to publisher's version	http://dx.doi.org/10.1128/jb.00790-16 Access to the full text of the published version may require a subscription.
Rights	© 2016, American Society for Microbiology. All Rights Reserved.
Embargo information	Access to this article is restricted until 6 months after publication by the request of the publisher.
Embargo lift date	2017-05-28
Item downloaded from	http://hdl.handle.net/10468/3459

Downloaded on 2017-09-05T01:11:30Z

1

2 **Progress in understanding of the molecular basis underlying functional diversification of**
3 **cyclic di-nucleotide turnover proteins**

4

5

6

7

8 **Ute Römling^{1*}, Zhao-Xun Liang², J Maxwell Dow³**

9

10 ¹Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE-171 77 Stockholm,
11 Sweden

12 ²School of Biological Sciences, Nanyang Technological University, Singapore

13 ³School of Microbiology, Biosciences Institute, University College Cork, Cork, Ireland

14

15

16 **Running title:** Diversity of cyclic di-GMP metabolizing proteins

17

18

19 Correspondence to Ute Römling, Ute.Romling@ki.se or Zhao-Xun Liang, ZXLiang@ntu.edu.sg

20

21

22 **Keywords:** cyclic di-nucleotide second messengers, GGDEF domain, EAL domain, HD-GYP domain,

23 DHH-DHHA1 protein

24 **ABSTRACT**

25 Cyclic di-GMP was the first cyclic di-nucleotide second messenger described, presaging the
26 discovery of additional cyclic di-nucleotide messengers in bacteria and eukaryotes. The GGDEF
27 diguanylate cyclase (DGC) and EAL and HD-GYP phosphodiesterase (PDE) domains conduct the
28 turnover of cyclic di-GMP. These three unrelated domains belong to superfamilies that exhibit
29 significant variations in function, to include both enzymatically active and inactive members with a
30 subset involved in synthesis and degradation of other cyclic di-nucleotides. Here we summarize
31 current knowledge of sequence and structural variations that underpin the functional diversification
32 of cyclic di-GMP turnover proteins. Moreover, we highlight that superfamily diversification is not
33 restricted to cyclic di-GMP signaling domains, as particular DHH/DHHA1 domain and HD domain
34 proteins have been shown to act as cyclic di-AMP phosphodiesterases. We conclude with a
35 consideration of the current limitations that such diversity of action places on bioinformatic
36 prediction of the roles of GGDEF, EAL and HD-GYP domain proteins.

37

38

39

40 INTRODUCTION

41 The di-nucleotide cyclic di-GMP is the most abundant second messenger in Bacteria. It promotes
42 the environmental life style switch between sessility and motility as well as the host-related life
43 style switch between acute and chronic/benign infection. A hallmark of the cyclic di-GMP signaling
44 network is an apparent redundancy of cyclic di-GMP turnover proteins encoded in one genome.
45 However many of these proteins have distinct N-terminal sensing and signaling domains,
46 suggesting that their activities in cyclic di-GMP turnover respond post-translationally to various
47 (and different) intra- and extra-cellular signals. In gross terms, the number of cyclic di-GMP
48 turnover proteins is linearly correlated with genome size within the different bacterial phyla with
49 *Thermotogae* having one of the highest cyclic di-GMP related "IQs", density of enzymes per Mbp,
50 with some species harboring over 100 cyclic di-GMP turnover proteins
51 (http://www.ncbi.nlm.nih.gov/Complete_Genomes/c-di-GMP.html). As in other domain
52 superfamilies, extensive sequence diversity exists. Here, we review the knowledge on the
53 translation of sequence diversity of cyclic di-GMP turnover proteins into functional diversity. We
54 conclude by discussing whether and how a unified nomenclature for cyclic di-GMP turnover
55 proteins can be established.

56

57 FUNCTIONAL DIVERSIFICATION OF THE GGDEF DOMAIN

58 The approx. 180 amino acid long GGDEF domain catalyzes synthesis of cyclic di-GMP from two
59 molecules of GTP with the release of pyrophosphate (Fig. 1; (1, 2)). So far, the GGDEF domain is the
60 only identified protein domain to carry out this specific condensation reaction. Even before
61 functional characterization, the GGDEF domain was recognized to be a structural homologue of the
62 adenylate cyclase domain, both belonging to the RRM (ferredoxin) fold palm domain family, which
63 includes other enzymes forming 3'-5' phosphodiester bonds such as reverse transcriptases, class A
64 and B DNA polymerases and RNA dependent RNA polymerases (3, 4). In approximately 40% of

65 proteins, the GGDEF domain is not only coupled to an N-terminal signaling domain, but also a C-
66 terminal EAL domain. Stand-alone GGDEF domains are rare and have not been characterized
67 extensively (5). The GGDEF domain frequently possesses suboptimal catalytic activity and requires
68 dimerization for the condensation reaction to occur at the active half-sites of the two monomers.
69 Dimerization can be further promoted by allosteric activation of the N-terminal sensor domain (6).
70 Various mechanisms of activation are emerging reflecting the diversity of cytoplasmic,
71 transmembrane and periplasmic signaling domains as well as linker and signal transducing
72 domains, which are potentially associated with sequence diversification of the turnover domain (1,
73 6-10). Notably, the DgcZ (YdeH) DGC is an active dimer with Zn²⁺ ion binding to inhibit the
74 catalytic activity (10). GGDEF domains can be differentiated into three major classes: enzymatically
75 functional domains; enzymatically functional domains, linked to an EAL domain; and enzymatically
76 non-functional domains ((Fig. 2); (11)). This classification is based on the homology of the entire
77 domain in combination with the conservation of the extended signature motif (Fig. 2; (12, 13)).

78

79 *Key residues in catalysis and allosteric regulation*

80 The GGDEF domain consists of the defining GG(D/E)EF sequence motif that includes the D/E
81 catalytic base and other residues intimately involved in substrate binding and coordination of one
82 of the two divalent cations (14). The position of the substrate GTP in the crystal structure(s) of
83 GGDEF domain proteins indicates the presence of the glycines provides space for the ribosyl sugar
84 and phosphates thus explaining conservation of these residues (Fig. 3; (14, 15)). In PleD, the most
85 well investigated di-guanylate cyclase for which a crystal structure is available, the guanine base is
86 bound in a pocket with N335 and D344 as key contact residues curtailed by apolar side chains of
87 L294, F331 and L247. D/E is the catalytic base, while K332 stabilizes the transition state. All those
88 residues are well conserved in catalytically competent diguanylate cyclases (for further
89 information see Fig. 2).

90 Non-functional GGDEF domains are usually characterized by a degenerate GGDEF motif as any
91 mutation within the GGDEF motif of catalytically active GGDEF domain proteins usually abolishes
92 the catalytic activity, although there are exceptions. For example, the GGDEF domain protein of
93 *Staphylococcus aureus* and *Staphylococcus epidermidis* with a well-conserved GGDEF motif has been
94 experimentally proven to be non-functional (16). The structural basis of non-functionality of
95 *Staphylococcal* GGDEF domains still remains an enigma. As to alteration in the signature motif, it is
96 fairly common that GGDEF domains contain a degenerate GG(D/E)EF motif with the first G not
97 conserved. Recent experimentally characterized proteins with a G>A or G>S substitution still
98 exhibit significant functionality demonstrating unexpected flexibility in the GGDEF containing
99 active site hairpin (Fig. 2; (17-19)).

100 Besides the gross classification into catalytically active and non-active GGDEF domains, the
101 inhibitory site (I-site), designated by the central signature motif RxxD is another functional feature
102 which characterizes the activity profile (14, 20). The I-site, which is formed at an intra- or
103 intermolecular interface bridged by a cyclic di-GMP dimer, variably extends beyond the central
104 conserved RxxD cyclic di-GMP binding motif and mediates allosteric non-competitive product
105 inhibition, feedback control of cyclic di-GMP synthesis (20, 21). The RxxD motif is absent in a
106 proportion of GGDEF domains; alternative mechanisms to control cyclic di-GMP synthesis have
107 been described for some of these proteins (6, 22, 23). A second recently discovered function of the
108 I-site is the participation in protein-protein interaction with cyclic di-GMP receptor, which ensures
109 a stringent specificity of cyclic di-GMP signaling even in the presence of cyclic di-GMP production
110 (21). In divergent GGDEF domain proteins (see below), a retained I-site in catalytically non-
111 functional GGDEF domains converts these domains into cyclic di-GMP receptors (24-27). It should
112 be noted that the enzymatic activity of the GGDEF domain can also be positively regulated by
113 cooperative binding of the GTP substrate (19).

114 Some GGDEF domains have diverged to be enzymatically nonfunctional. These nonfunctional
115 GGDEF domains can act as sensor domains that bind the substrate GTP, thereby allosterically
116 regulating the enzymatic activity of a C-terminal EAL phosphodiesterase (28). In this way the
117 degenerate GGDEF motif is involved in allosteric control (20, 29). A surprisingly high catalytic
118 plasticity has been demonstrated as a highly degenerate GGDEF domain has been shown to display
119 ATPase activity, albeit at suboptimal levels (30).

120

121 *Alternative cyclic dinucleotides synthesized by GGDEF domain proteins*

122 A hallmark of binding of nucleotide and sugar derivatives to proteins is the low stringency of the
123 specificity of the binding site. Accordingly, alteration of few amino acids can alter substrate
124 specificity of nucleotides and sugars. Although it is the common perception that cyclic di-GMP
125 synthases can be readily identified in bacterial genomes as being members of the GGDEF domain
126 superfamily, GGDEF domain proteins that predominantly synthesize cyclic GMP-AMP, but also
127 cyclic di-GMP and cyclic di-AMP have recently been identified (31). The relative specificity of cyclic
128 GMP-AMP synthase activity as opposed to stringently using GTP as substrate on this specific
129 protein scaffold is determined by the amino acid serine, which has replaced aspartate 344
130 (designation according to PleD sequence), a key contact residue in the base-binding pocket. As the
131 exchange of aspartate for serine in an established di-guanylate cyclase did not lead to the
132 conversion into a cyclic GMP-AMP synthase, additional features of the protein scaffold must also
133 contribute to substrate specificity.

134

135 *Specificity in regulatory action*

136 In general, GGDEF domains encoded by a single genome are functional paralogues, which have a
137 low amino acid sequence identity/similarity below 40%, while orthologues with identical domain
138 structure and high sequence identity can be found even in distantly related species (32). One of the

139 hallmarks of cyclic di-GMP signaling is a relative or absolute specificity of a phenotypic output of an
140 individual chromosomally encoded GGDEF domain protein. This specificity is partly explained by
141 the close proximity of signal production/degradation with receptor and/or effector proteins
142 mediated through protein-protein interactions, a first example being the involvement of the I-site
143 of a GGDEF domain in interaction with an EAL domain cyclic di-GMP receptor (21, 33). Interactions
144 between the EAL domain protein YciR and diguanylate cyclase YdaM control a key step in *E. coli*
145 biofilm formation through modulation of localised cyclic di-GMP levels (34). Functionality is also
146 provided, however, by specific protein-protein interactions that are independent of the catalytic
147 activity (19, 35). In this case, the xxDxDx motif, which is highly conserved in GGDEF domains, is
148 required for the interaction with the HD-GYP domain. HD-GYP::GGDEF complex formation serves to
149 control motility through recruitment of a PilZ domain protein and interaction with the pilus
150 biogenesis machinery (35, 36). Overall, these data indicate that GGDEF domain proteins possess
151 several protein interaction interfaces, which participate in the formation of supramolecular
152 complexes.

153

154 **FUNCTIONAL DIVERSIFICATION OF THE EAL DOMAIN**

155 The EAL domain was the first identified cyclic di-GMP specific phosphodiesterase, and remains the
156 most well characterized (Fig. 4, 5; Fig. S1; (2, 37, 38)). The product of EAL phosphodiesterase
157 activity is the di-nucleotide pGpG, while hydrolysis of pGpG into GMP is considered to be too slow
158 to be physiologically relevant. EAL phosphodiesterases require a divalent cation for enzymatic
159 activity, which in most cases is Mg²⁺ or Mn²⁺ ion, while Ca²⁺ and Zn²⁺ efficiently inhibit the
160 enzymatic activity (39, 40). Catalytically active EAL domains usually have a high substrate affinity
161 in the physiological nanomolar range and cyclic di-GMP binding can increase the dimerization
162 affinity (41). Although monomers can be catalytically active, dimerization substantially enhances
163 protein stability and catalytic activity (37).

164

165 *Key residues for activity*

166 Systematic alanine substitutions of conserved signature amino acids have given insights into the
167 catalytic mechanism, even before a crystal structure had become available (42, 43). That work
168 showed that the EAL motif is part of a larger conserved signature motif that is required for catalytic
169 activity including amino acids required for binding of divalent cations, the substrate and catalysis.
170 In addition, a flexible loop ("loop 6") extensively characterized in (β/α) barrel proteins mediates
171 dimerization and controls substrate and cation binding, thus being required for catalytic activity (42,
172 44). The findings from this mutagenesis study enabled the differentiation of EAL domains in three
173 classes: catalytically active, potentially catalytically active and catalytically inactive EAL domains
174 (32, 42), thus facilitating the prediction of the function of further EAL domains. Based on the
175 functional characterization of additional EAL domains, a further sub-classification can be made (see
176 Fig. 4).

177 The crystal structures of several EAL domain-containing proteins revealed that these proteins
178 possess a protein fold variant of the (β/α) TIM-barrel structure arranged as eight alternating alpha
179 helices and beta-strands (Fig. 5; (44)). This arrangement of secondary structures is found in over 50
180 diverse protein superfamilies (45). The functionality of this highly conserved arrangement of
181 secondary structures is highly flexible as these protein families bind different substrates and
182 catalyze different reactions. In case of the light-inducible phosphodiesterase Blrp1 of *Klebsiella*
183 *pneumoniae*, interdomain interaction between the sensor domain and a non-conserved connector
184 in the EAL domain of only four amino acids in length controls the catalytic activity in response to
185 light (Fig. 5A; (44)).

186

187 *Classification of divergent domain members*

188 As with the GGDEF domain, the EAL domain superfamily contains diverged members. Most EAL
189 domains are class I EAL domains, which possess a N-terminal signaling domain and features
190 substantial, but still suboptimal catalytic activity in the non-activated state, requiring the correct
191 positioning of conserved loop 6 (42, 44). Class II EAL domains potentially possess catalytic activity
192 with deviations of some amino acids from the conserved signature motifs; they are most poorly
193 characterized. Of note, catalytically active EAL-only domain proteins comprise a specific subgroup
194 within the class II family. Class III EAL domains can already be recognized by bioinformatic analysis
195 to be catalytically inactive, since class III domains possess deviations from the conserved signature
196 motifs of active enzymes in several determinative positions. Nevertheless some class III domains
197 can still bind cyclic di-GMP, thus serving as cyclic di-GMP receptors (class IIIa), whereas others are
198 unable to bind the di-nucleotide (Fig. 5B; (class IIIb)).

199 Cyclic di-GMP binding and non-binding EAL domains cannot be distinguished with certainty (Fig.
200 4). However, in both cases, several conserved signature amino acids are missing and loop 6 is not
201 conserved. Binding of cyclic di-GMP to a receptor EAL domain allosterically controls subsequent
202 events. In the conserved Lap system with the GGDEF-EAL receptor LapD, interactive inside-
203 out/outside-in signals mediated by the HAMP domain couple cytoplasmic cyclic di-GMP binding to
204 reinforcement of periplasmic protein-protein interactions controlling e.g. periplasmic proteolysis of
205 cell surface proteins (46, 47). Interestingly, homologous GGDEF-EAL receptors have variations in
206 their cyclic di-GMP binding sites and bind cyclic di-GMP in different conformations, which reflects
207 the structural polymorphism of this second messenger (48, 49) as well as binding site flexibility
208 (Fig. 5C; (50)). Such polymorphisms make it still challenging to predict cyclic di-GMP binding
209 residues by bioinformatics.

210 Catalytically inactive, non-cyclic di-GMP binding EAL proteins function solely through protein-
211 protein interactions. Several well-investigated class IIIb proteins of *Escherichia coli* and *Salmonella*
212 *typhimurium*, YdiV and *Salmonella* specific STM1697, bind to the major flagella regulator FlhDC

213 with apparently similar, but highly distinct interfaces (51-53). Furthermore, the class IIIb protein
214 YdiV, interacts in complex with FlhDC, with the ClpXP protease guiding FlhDC for degradation (54)
215 and regulates other physiological traits besides motility (55).

216

217 *Regulation of dual-function diguanylate cyclase-phosphodiesterases*

218 Of particular complexity is the regulation of the activity of GGDEF-EAL domain proteins in case
219 where the two domains are both catalytically functional (56). Notably, the three DGCs and three
220 PDEs of *Komatsugaeibacter xylinus* that affect cellulose production, the first biological function
221 recognized to be affected by cyclic di-GMP signaling, are GGDEF-EAL domain proteins, and both
222 domains are predicted to be functional by bioinformatics analysis (39). Differential regulation of
223 the catalytic activity of these domains can include allosteric regulation by ligand binding, signal
224 perception or protein-protein interactions which favors one catalytic activity over the other (7, 57-
225 60), but could also include a combination of regulatory mechanisms such as proteolytic cleavage in
226 combination with signal perception (61). This points to a multifactorial regulation of catalytic
227 activity *in vivo*. However, catalytically active domains can even predominantly affect certain aspects
228 of physiology through protein-protein interactions. For example, the GGDEF-EAL
229 phosphodiesterase YciR of *E. coli* affects expression of *csgD*, a major biofilm regulator, through
230 interaction with a DGC and a transcriptional regulator, which inhibits biofilm formation (34).

231

232 *A phosphodiesterase involved in pGpG degradation*

233 The observations that the EAL domain hydrolyses cyclic di-GMP into 5'-pGpG (Fig. 1) have raised
234 the question of the possible cellular role and fate of this di-nucleotide product (62). As an inhibitor
235 of the enzymatic activity of particular EAL domain proteins, this molecule could potentially impinge
236 on cyclic di-GMP levels and signaling. Furthermore, it has been suggested that this nano-RNA is a
237 signaling molecule in its own right, involved in the initiation of transcription by RNA polymerase

238 (63). Two classes of enzymes are implicated in 5'-pGpG degradation: a subgroup of HD-GYP domain
239 phosphodiesterases that can hydrolyse both cyclic di-GMP and 5'-pGpG (see below) and the
240 oligoribonuclease Orn, recently identified as the primary degradative enzyme for 5'-pGpG in
241 *Pseudomonas aeruginosa* (64, 65). Homologues of Orn are widely distributed in bacteria, although
242 Cohen and colleagues (65) identified over 200 species that lack an Orn homolog, but have EAL and
243 HD-GYP domain proteins, as well as over 100 species that lack both an Orn homolog and EAL
244 domains, but have HD-GYP domain proteins. Thus in some bacteria, HD-GYP domain proteins may
245 influence cyclic di-GMP levels both directly, by hydrolysis of the nucleotide, and indirectly by
246 preventing product inhibition of the activity of EAL domain enzymes.

247

248 **FUNCTIONAL DIVERSIFICATION OF THE HD-GYP DOMAIN**

249 There are fewer studies of HD-GYP domain proteins compared to those with the GGDEF and EAL
250 domains. Although well-studied model organisms harbor mostly EAL domain phosphodiesterases,
251 the HD-GYP domain is one third as abundant throughout the phylogenetic tree
252 (https://www.ncbi.nlm.nih.gov/Complete_Genomes/c-di-GMP.html). The prototype of an HD-GYP
253 domain protein is the response regulator RpfG from *Xanthomonas campestris* (36, 66). This protein
254 is part of a two component system that affects expression of multiple virulence functions in this
255 plant pathogen (67, 68). *In vitro*, RpfG converts cyclic di-GMP to GMP via the intermediate 5'-pGpG
256 dependent on Mn²⁺ (66, 69). Alanine substitution within the signature HD dyad leads to loss of both
257 enzyme activity and regulatory action (66). In contrast, although alanine substitutions in the
258 signature GYP motif have little or no effect on enzyme activity, they do counteract interaction of
259 RpfG with particular GGDEF domain proteins to modulate a specific subset of RpfG mediated
260 phenotypes (35, 66, 70).

261

262 *Diversity in metal binding*

263 The crystal structure of the enzymatically-active HD-GYP phosphodiesterase *PmGH* from
264 *Persephonella marina* EX-H1 unexpectedly showed a trinuclear Fe center with iron in two redox
265 states as Fe(II) and central Fe(III) buried at the bottom of the cavity forming the c-di-GMP binding
266 site (Fig. 6; (71)). In general, the HD domain superfamily of enzymes has been shown to catalyze
267 phosphomonoesterase and phosphodiesterase reactions depending on their catalytic metal center
268 being mono- or binuclear, respectively. Variations in the metallic center of the HD-GYP domain
269 were seen in the structure of the unconventional, catalytically inactive Bd1817 from *Bdellovibrio*
270 *bacteriovorans* (72) and PA4781, a two component regulatory protein from *Pseudomonas*
271 *aeruginosa* (73) which harbor bi-nuclear metal centers, although of a distinct nature.

272 A phylogenetic comparison of HD-GYP domains showed a distinct separation into two evolutionary
273 groups independent of the type of associated regulatory and/or sensory domain (71) with seven
274 out of the eight *PmGH* metal ligand residues shared (Fig. 7; (71)). The variable ligand which
275 corresponds to E185 in *PmGH* is embedded in the signature motif E/D-T-G for the *PmGH* subfamily.
276 E185 has been predicted to be determinative for a three-metal center valency (71, 74). Conversely,
277 the other subfamily primarily presents a tyrosine or phenylalanine (Y/F) and lacks a unique
278 signature.. The separation of HD-GYP proteins into these two subfamilies is not entirely clear-cut
279 though (Fig. 7); (73), (75)). For example, RpfG from *X. campestris*, despite phylogenetically
280 clustering within the E/D-T-G subgroup, aligns a glycine in place of the E/D residue, as well as
281 variation in a H-site metal ligand (Fig. 7). Thus RpfG is more likely to possess a binuclear metal ion
282 center.

283 Recent work has provided evidence that the differences in the occupancy of the metal site and the
284 redox status affect catalysis (74). The activity of VCA0681 requires Fe(II) at the bimetallic center,
285 and derivatives with Fe(III) are inactive suggesting that the activity of this protein is redox-
286 regulated (76). Also isolated TM0186 from *Thermotoga maritima* with two Fe(III) atoms is inactive;
287 reduction to Fe(II) enables the enzyme to generate 5'-pGpG but not GMP. Additional

288 supplementation with either Mn(II) or Fe(II) leads to production of GMP. The phylogenetic
289 clustering of TM0186 within the E/D-T-G subgroup of HD-GYP domain proteins suggests that it has
290 a tri-metallic center. Furthermore, a variant protein with an alanine substitution of the glutamate
291 generates only 5'-pGpG as a product. The findings point to the association of a tri-metallic center
292 with the ability to generate GMP from 5'-pGpG. Also, the action of HD-GYP domains in converting 5'-
293 pGpG to GMP suggests regulation by the intracellular availability of metals and metal site
294 occupancy. Finally, catalytically inactive S02541 HnoD from *Shewanella oneidensis* and PA2572
295 from *P. aeruginosa* are variant at the HD dyad (SE and YN respectively) and have only 1 conserved
296 residue involved in metal chelation (77, 78); as a result, these proteins may exert their effect
297 through protein interactions involving the GYP motif (77, 78).

298

299 *Diversity in substrate binding and catalysis*

300 Determination of the structure of *PmGH* in complex with the substrate cyclic di-GMP and final
301 reaction product GMP has revealed the mode of binding and shed light on the possible catalytic
302 mechanism (71, 79). Adequate space is available for the substrate to bind and both hydrolysable
303 phosphates to interact with the metal center to sequentially hydrolyze cyclic di-GMP to GMP. Cyclic
304 di-GMP is bound in a *cis* conformation (71), in contrast to the more extended conformation
305 observed when cyclic di-GMP is bound to EAL domain proteins (80) or predicted in binding to the
306 HD-GYP domain protein PA4108 (81).

307 The structural analysis of *PmGH*-cyclic di-GMP complex shows that the bound cyclic dinucleotide
308 interacts with the central (M-site) Fe(III) and is involved in diverse hydrogen bonds and
309 hydrophobic interactions (Fig. 6). As in RpfG, in *PmGH* alanine substitutions of six residues involved
310 in metal binding in addition to the HD dyad (H221, D222) (see Fig. 7) essentially abolish or
311 markedly reduce the phosphodiesterase activity. Alanine mutation of other conserved residues
312 near the metal center (D183, D308, and K225) have a similar impact on activity (71). Alanine

313 substitutions of residues implicated in cyclic di-GMP recognition do not, however, result in a
314 substantial decrease in catalytic activity (71). The proposed enzymatic mechanism is that M-site
315 Fe(III) directly interacts with a non-bridging oxygen of one of the scissile phosphate diesters of
316 cyclic di-GMP to provide a strong Lewis acid catalyst, whereas a metal-activated bridging hydroxide
317 ion of the M-H Fe pair is the likely nucleophile for the hydrolysis of the scissile bond (71). The
318 occurrence of a hydroxide ion bridging ligand is consistent with the metal-ligand bond lengths (72,
319 82). The structure does not reveal how the O3' leaving group is protonated, however.

320 The structure of PA4781 reveals potential steric hindrance of cyclic di-GMP binding by a glutamate
321 at position 314 (73). Accordingly, the purified enzyme has a relatively low affinity for cyclic di-GMP
322 ($K_M \sim 120 \mu\text{M}$) compared to 5'-pGpG ($K_M \sim 27 \mu\text{M}$). In other enzymatically active HD-GYP domain
323 proteins, position 314 is occupied by an alanine (see Fig. 7), and an E314A variant of PA4781 shows
324 substantially enhanced affinity for cyclic di-GMP (81). Detailed kinetic analyses indicate that
325 PA4781 has a low enzymatic activity but hydrolyses 5'-pGpG more effectively than cyclic di-GMP
326 (81). Although similar kinetic experiments on other HD-GYP domain proteins have not been
327 reported, the available evidence suggests that differences in the relative activity against 5'-pGpG
328 compared to cyclic di-GMP do occur (83) (76) (84) (77) (66, 69, 71).

329

330 *Structural insights into the multifunctional roles of HD-GYP domains*

331 A sequence-based analysis identified the GYP signature motif of HD-GYP proteins as part of a larger
332 widely conserved motif HHExxDGxGYPxxxxxxI (66). The *PmGH* structure suggests an extension of this
333 consensus motif to HHExxDGxGYPxxxxxxI, to include a conserved isoleucine residue (I294 in
334 *PmGH*) that stabilizes the structure of the loop by hydrophobic interactions with G284 from the
335 GYP motif (71). The structural conservation of the 'GYP loop' (Fig. 6) (73) between *PmGH* and
336 PA4781 suggests that it is integral to the functions(s) of HD-GYP domain proteins. The GYP motif is

337 critical for protein-protein interactions of RpfG with specific GGDEF domain proteins in *X.*
338 *campestris*, but is not necessary for the phosphodiesterase activity (66).

339 The available evidence suggests that the HD-GYP domain of RpfG can also interact with proteins of
340 other classes, including the transcriptional regulator NtrC (36, 85). Furthermore the enzymatically
341 inactive HD-GYP domain response regulator HnoD can inhibit the activity of the EAL domain
342 response regulator HnoB to regulate cyclic di-GMP levels in *Shewanella oneidensis* (77). The
343 mechanistic basis of this inhibition is not known. Different HD-GYP domain proteins within the
344 same organism may interact with different partners *in vivo*, although this remains to be tested
345 experimentally.

346 The structure of the *PmGH* HD-GYP complex with cyclic di-GMP reveals that Y285 of the GYP motif
347 is placed inside the substrate-binding pocket, where it H-bonds to cyclic di-GMP (Fig. 6). This
348 presents a conundrum for the action of RpfG. If GGDEF domains interact directly with Y285, they
349 need to intercalate with the inner side of the HD-GYP nucleotide-binding pocket. This would
350 prevent cyclic di-GMP binding and phosphodiesterase activity, although such effects have not been
351 observed *in vitro* (35). An intriguing alternative is that RpfG involvement in protein-protein
352 complexes is determined not only by cyclic di-GMP binding but also by conformational alterations
353 associated with cyclic di-GMP degradation, which would be 'reported' via the GYP loop. In this way,
354 RpfG would act as a trigger enzyme for protein complex formation and regulation similar as
355 suggested for the EAL domain protein YciR of *Escherichia coli* (34). However mutation of the HD
356 dyad of the HD-GYP domain of RpfG does not significantly affect its *in vivo* interaction with GGDEF
357 domain proteins, as revealed by FRET analysis (35). Only further work can reveal whether
358 particular regulatory actions of HD-GYP domain proteins occur independently of their ability to
359 bind or hydrolyse cyclic di-GMP or 5'-pGpG.

360

361 *Further substrates for HD-GYP domain proteins*

362 In addition to cyclic di-GMP, bacteria have been shown to utilise cyclic di-AMP and most recently
363 the dinucleotide 3'3'-cyclic GMP-AMP as intracellular signal molecules. The latter molecule was
364 discovered in *Vibrio cholerae* as a regulator of chemotaxis and of factors contributing to
365 colonisation of the intestine (86). A screen of potential phosphodiesterases for 3'3'-cyclic GMP-
366 AMP from *V. cholerae* identified three HD-GYP domain proteins, VCA0210, VCA0681 and VCA0931
367 which were capable of hydrolysis of the cyclic dinucleotide into 5'-pApG, with VCA0681 having an
368 additional 5' nucleotidase activity to generate 5'-ApG (87). The nucleotidase and phosphodiesterase
369 activities were associated with the HD and HD-GYP domains respectively that are present in
370 tandem (87). All three proteins hydrolyse 3'3'-cyclic GMP-AMP specifically, with no activity against
371 other cyclic GMP-AMP forms with different phosphodiester linkages, to include the mammalian
372 innate immunity regulator 2'3'-cGMP-AMP. Variant VCA0681 proteins with alanine substitutions in
373 the signature HD dyad and GYP motif have no detectable activity (87)(Gao et al., 2015), in contrast
374 to the role of the GYP motif in *PmGH* and *RpfG* (Bellini et al., 2014; Ryan et al, 2010).

375

376 **FUNCTIONAL DIVERSIFICATION OF CYCLIC DI-AMP PHOSPHODIESTERASES**

377 The functional diversification also extends to other cyclic di-nucleotide signaling networks. As the
378 currently most prominent example, DHH/DHHA1 proteins usually function as phosphatase or
379 phosphodiesterases for hydrolyzing a wide variety of substrates that range from pyrophosphate to ssDNA.
380 The substrate specificity of DHH/DHHA1 enzymes is usually governed by the DHHA1 domain rather
381 than the DHH domain. A bioinformatics search of potential phosphodiesterases for cyclic di-AMP, a
382 universally essential cyclic di-nucleotide second messenger in Gram-positive bacteria (88, 89), led to the
383 discovery of a DHH domain protein (YybT or GdpP) from *B. subtilis* as a cyclic di-AMP
384 phosphodiesterase (30). GdpP is a metal ion-dependent phosphodiesterase that breaks down cyclic di-
385 AMP into 5'-pApA at physiologically relevant substrate concentrations (μM). In accordance with its
386 specificity towards cyclic di-AMP, the DHHA1 domain of GdpP does not share significant sequence

387 homology with the DHHA1 domains of other DHH/DHHA1 proteins. Importantly, a number of Arg
388 residues critical for the binding of polyphosphate, RNA, or ssDNA in other DHHA1 domain proteins
389 (e.g. RecJ and YtqI) are not conserved in YybT. Another DHH/DHHA1 protein (Pde2) that lacks the
390 PAS and GGDEF domain of GdpP and degrades cyclic di-AMP into AMP was discovered in *S.*
391 *pneumoniae* (90). Pde2 is an ortholog of *B. subtilis* YtqI (also named NrnA) that was claimed to be
392 responsible for degrading nanoRNA (RNA oligonucleotides of ≤ 5 nucleotides) and dephosphorylating
393 pAp to AMP (91, 92)

394 In addition to the DHH-DHHA1 proteins, a subfamily of HD domains possesses cyclic di-AMP
395 phosphodiesterase activity. The first example is the *Listeria monocytogenes* protein PgpH (93).
396 Biochemical and structural studies revealed binding of cyclic di-AMP with high affinity ($K_d = 0.3\text{--}0.4$
397 μM) and hydrolysis to 5'-pApA in the presence of divalent metal ions such as Mn^{2+} and Fe^{2+} .

398 The discovery of the DHH/DHHA1 and HD-domain based phosphodiesterases for degrading
399 cyclic di-AMP mirrors the converging evolution of the EAL and HD-GYP domains involved in cyclic
400 di-GMP degradation. Although the structural basis for the recognition of cyclic di-AMP by the PDEs
401 remains to be fully defined, the crystal structure of the stand-alone DHH/DHHA1 protein Rv2837c
402 in complex with the hydrolytic intermediate 5-pApA suggests that a set of residues from both DHH
403 and DHHA1 domains contribute to the binding of cyclic di-AMP (94). Even assuming that only two
404 families of cyclic di-AMP phosphodiesterases are found in nature, identification of the members of
405 the two families by bioinformatic should still proceed with caution and experimental validation is
406 necessary.

407

408 **CONCLUDING REMARKS**

409 As outlined above, diversity in the function of GGDEF, EAL and HD-GYP domains is evident in terms
410 of enzymatic activity, the ability to synthesize or degrade alternate di-nucleotides as well as in
411 interactions with other proteins. This functional diversity certainly extends to other cyclic di-

412 nucleotide turnover proteins such as the DHH/DHHA1 enzymes. Further biochemical and
413 structural work is required to gain knowledge of the molecular bases for the substrate specificity or
414 preference. Work on stringent cyclic mononucleotide synthases shows that quite limited variations
415 give rise to different specificities; cyclic GMP synthases can be experimentally changed to cyclic
416 AMP synthases and vice versa by just two or three amino acid exchanges (95, 96). On the other
417 hand, relaxed enzymes can produce several different cyclic nucleotides (97). In addition, a three
418 amino acid replacement in the human cyclic di-nucleotide synthase cGAS changes the
419 phosphodiester linkage specificity so that 3'3' cyclic GMP-AMP rather than the non-canonical 2'3'
420 cyclic GMP-AMP is synthesized (98). The three new residues incorporated were the determinative
421 amino acids in DncV, a bacterial homolog of cyclic GMP-AMP synthase (98). Indeed ancient cGAS is
422 a 3'3' cyclic GMP-AMP synthase (99). As outlined above, distinct GGDEF domain proteins that have
423 been shown to produce cyclic GMP-AMP (31) and some HD-GYP domain phosphodiesterases can
424 have cyclic GMP-AMP hydrolytic activity (87). Similar changes in substrate specificity to those
425 within the GGDEF and HD-GYP domain protein families could also occur within the EAL domain. In
426 addition, novel enzymes with cyclic di-nucleotide turnover activity might be recognized. Recently,
427 CpdB which is characterized by a diffusion determined speed of 3'-AMP hydrolytic activity, was also
428 shown to hydrolyze cyclic di-AMP with a reasonable turnover rate (100). With the current stage of
429 knowledge, it thus appears difficult to assign substrate specificity and product outcome with
430 certainty by bioinformatics. Thus, current species-specific nomenclatures might limit the
431 comparison to distantly related species, which frequently harbor orthologous proteins, while
432 functional paralogues of di-nucleotide turnover proteins dominate within a species. The elucidation
433 of the structures of cyclic di-GMP turnover domains in complex with other cyclic di-GMP turnover
434 domains and other interacting proteins will also be necessary to provide a deeper understanding of
435 the regulatory action of the diversity of these families of signaling proteins and to fully explore their
436 true functions. This is certainly the case for those proteins that may be multifunctional and which

437 may regulate different functions through protein-protein interactions and modulation of cyclic di-
438 GMP levels.

439 **Acknowledgement**

440 Cyclic di-GMP research of UR is funded by the Swedish Research Council for Natural Sciences and
441 Engineering (621-2013-4809). Research in LZX's laboratory is supported by a Tier II ARC grant
442 from MOE, Singapore. The work in the laboratory of JMD has been supported in part by grants
443 awarded by Science Foundation Ireland (SFI 07/IN.1/B955, SFI 07/IN.1/B955/IRPs, SFI
444 11/TIDA/B2036) and the Wellcome Trust (project grant WT093314MA).

445

446

447 **Funding information**

448 The Swedish Research Council for Natural Sciences and Engineering (621-2013-4809) to UR. The
449 research in LZX's laboratory is supported by a Tier II ARC grant from MOE, Singapore.

450

451

452

453 **Figure legends**

454

455 **FIG 1** Enzymes involved in the turnover of second messengers cyclic di-GMP (B) and cyclic di-AMP
456 (B). GGDEF domain proteins are cyclic di-GMP synthases (2), but a few members can preferentially
457 synthesize cyclic GMP-AMP (31). Cyclic di-GMP is degraded by EAL domain or HD-GYP domain
458 phosphodiesterases into 5'-pGpG and GMP, respectively (66). 5'-pGpG is further hydrolyzed to GMP
459 by the oligoribonuclease Orn. Cyclic di-AMP is synthesized by the DAC domain and hydrolysis has
460 been demonstrated by HD and DHH/DHHA1 domain proteins. Major phenotypes affected upon
461 cyclic di-nucleotide synthesis in many bacteria are indicated.

462

463 **FIG 2** Classification of GGDEF domains according to protein structure and conservation of signature
464 motifs. Amino acids on a grey background interact with the substrate in the diguanylate cyclase
465 PleD. K₃₃₂ stabilizing the transition state is on a cyan background. The RxxD I-site core motif is in
466 blue. Unconventional amino acids still conferring enzymatic activity are on a blue background.
467 Amino acids conferring cyclic GMP-AMP specificity are on a green background. Amino acids
468 involved in the interaction with the HD-GYP domain are underlined. Conserved amino acids in
469 color. GGDEF domain protein names are in black and GGDEF-EAL proteins in green. Unconventional
470 GGDEF domain names in violet and cGMP-AMP synthesizing proteins in orange. Protein designation
471 in Supplemental material. Modified after (32).

472

473 **FIG 3** Ribbon diagram of the GGDEF domain of PleD binding the substrate analog GTP α S (PDB code:
474 2v0n). A. Amino acids interacting with the substrate analog α S-GTP (including Lys₄₄₂ and Arg₄₄₆
475 interacting with the phosphate group and the Mg²⁺ ions (Asp₃₂₇ and Glu₃₇₀) (1, 6, 15) are indicated. Mg²⁺
476 ions in green. B. Amino acid motifs providing additional functionality to GGDEF domains. R₃₅₉XXD₃₆₂ is

477 the core motif of the I-site. The $\text{xxD}_{327}\text{xD}_{329}$ motif was demonstrated in protein-protein interactions in
478 GGDEF domain proteins others than PleD.

479

480 **FIG 4** Classification of EAL domains according to protein structure and conservation of signature
481 motifs. The catalytic base glutamate is shown in red. In green, amino acids involved in Mg^{2+} binding;
482 in blue, amino acids involved in substrate binding. Alternative amino acids involved in cyclic di-
483 nucleotide binding are underlined. The glutamate stabilizing loop 6 is shown in orange. Loop 6
484 amino acids are on a grey background. Names of EAL proteins in black, EAL only proteins in red
485 and GGDEF-EAL proteins in green. Protein designation in Supplemental material. Modified after
486 (32).

487

488 **FIG 5** Substrate binding by EAL domains. A. Ribbon diagram structure of the EAL domains of BlrP1,
489 a fully functional class I PDE activated by light (44) and YahA (41) binding to the substrate cyclic di-
490 GMP. In the middle, enlarged view of the cyclic di-GMP binding site of BlrP1. Cations are shown in
491 violet and pink. Cyclic di-GMP is shown as sticks with carbon atoms colored yellow. B. Comparison
492 of electrostatic surface representation of class III EAL domains FimX of *P. aeruginosa* and YdiV of *E.*
493 *coli*. While the cyclic di-GMP binding site of class IIIa FimX is conserved (model is shown with cyclic
494 di-GMP bound), the cyclic di-GMP binding pocket is not conserved in class IIIb member YdiV. The
495 electrostatic surface potential shows highly electronegative (red) and electropositive patches
496 (blue) of the two proteins. C. Ribbon diagram structure of three Class IIIa cyclic di-GMP binding EAL
497 domains ($\text{EAL}_{\text{FimX_PSEAE}}$ (Q9HUK6 of *P. aeruginosa*), $\text{EAL}_{\text{XcFimX}}$ (A0A0H2X6E4 of *Xanthomonas*
498 *campestris* pv. *campestris*) and $\text{EAL}_{\text{LapD_Psfluor}}$ (Q3KK31 of *Pseudomonas fluorescens* Pf0-1). Note the
499 different conformations and binding modes of cyclic di-GMP, which is displayed as sticks with
500 carbon atoms in yellow, oxygen in red, phosphate in orange and nitrogen in blue.

501

502 **FIG 6** Substrate binding by the HD-GYP domain of PmGH. A: Surface representation of the PmGH
503 HD-GYP domain monomer subunit showing the binding cavity for cyclic di-GMP, which is
504 represented in stick mode and colored by atom type. B: Superposition of the structures of PmGH
505 bound to cyclic di-GMP and GMP. Both nucleotides are shown in stick mode. Bonding interactions
506 are represented by dashed lines. The central metal iron has been labeled as the middle site (M) and
507 the two flanking metal sites as H and G, to reflect their proximity to the HD and GYP motifs,
508 respectively. Residues that interact with cyclic di-GMP include Y285 of the GYP motif. Red spheres
509 represent solvent and SIN-1 a succinate molecule (71).

510

511 **FIG 7** Primary sequence alignment of HD-GYP domains from proteins that have been characterized
512 structurally and/or enzymatically reveals the diversity within the domain. Protein designation in
513 supplemental material. The top line indicates the helices in the structure of *PmGH* with an
514 annotation of the inter-helix loops. Metal ligands are given in red, proposed catalytic residues are
515 given in green. The GYP motif is highlighted in cyan and the substrate binding ligands in magenta.
516 The region of the sequences with consensus motifs E(D)TG/YTY are highlighted in yellow. (Note
517 that these are not fully conserved). The blue triangle points to the E residue in PA4781 that may act
518 in steric hindrance of cyclic di-GMP binding.

519

520 **References**

- 521 1. **Schirmer T.** 2016. C-di-GMP Synthesis: Structural Aspects of Evolution, Catalysis and
522 Regulation. *J Mol Biol* **428**:3683-3701.
- 523 2. **Schirmer T, Jenal U.** 2009. Structural and mechanistic determinants of c-di-GMP signalling.
524 *Nat Rev Microbiol* **7**:724-735.
- 525 3. **Anantharaman V, Iyer LM, Aravind L.** 2010. Presence of a classical RRM-fold palm domain
526 in Thg1-type 3'- 5' nucleic acid polymerases and the origin of the GGDEF and CRISPR
527 polymerase domains. *Biol Direct* **5**:43.
- 528 4. **Pei J, Grishin NV.** 2001. GGDEF domain is homologous to adenylyl cyclase. *Proteins* **42**:210-
529 216.
- 530 5. **Deepthi A, Liew CW, Liang ZX, Swaminathan K, Lescar J.** 2014. Structure of a diguanylate
531 cyclase from *Thermotoga maritima*: insights into activation, feedback inhibition and
532 thermostability. *PLoS One* **9**:e110912.
- 533 6. **Wassmann P, Chan C, Paul R, Beck A, Heerklott H, Jenal U, Schirmer T.** 2007. Structure
534 of BeF3- -modified response regulator PleD: implications for diguanylate cyclase activation,
535 catalysis, and feedback inhibition. *Structure* **15**:915-927.
- 536 7. **Mills E, Petersen E, Kulasekara BR, Miller SI.** 2015. A direct screen for c-di-GMP
537 modulators reveals a *Salmonella Typhimurium* periplasmic L-arginine-sensing pathway. *Sci*
538 *Signal* **8**:ra57.
- 539 8. **De N, Navarro MV, Raghavan RV, Sondermann H.** 2009. Determinants for the activation
540 and autoinhibition of the diguanylate cyclase response regulator WspR. *J Mol Biol* **393**:619-
541 633.
- 542 9. **Malone JG, Jaeger T, Manfredi P, Dotsch A, Blanka A, Bos R, Cornelis GR, Haussler S,**
543 **Jenal U.** 2012. The YfiBNR signal transduction mechanism reveals novel targets for the
544 evolution of persistent *Pseudomonas aeruginosa* in cystic fibrosis airways. *PLoS Pathog*
545 **8**:e1002760.
- 546 10. **Zahringer F, Lacanna E, Jenal U, Schirmer T, Boehm A.** 2013. Structure and signaling
547 mechanism of a zinc-sensory diguanylate cyclase. *Structure* **21**:1149-1157.
- 548 11. **Seshasayee AS, Fraser GM, Luscombe NM.** 2010. Comparative genomics of cyclic-di-GMP
549 signalling in bacteria: post-translational regulation and catalytic activity. *Nucleic Acids Res*
550 **38**:5970-5981.
- 551 12. **Kulasekara H, Lee V, Brencic A, Liberati N, Urbach J, Miyata S, Lee DG, Neely AN, Hyodo**
552 **M, Hayakawa Y, Ausubel FM, Lory S.** 2006. Analysis of *Pseudomonas aeruginosa*
553 diguanylate cyclases and phosphodiesterases reveals a role for bis-(3'-5')-cyclic-GMP in
554 virulence. *Proc Natl Acad Sci U S A* **103**:2839-2844.
- 555 13. **Römling U.** 2005. Characterization of the rdar morphotype, a multicellular behaviour in
556 Enterobacteriaceae. *Cell Mol Life Sci* **62**:1234-1246.
- 557 14. **Chan C, Paul R, Samoray D, Amiot NC, Giese B, Jenal U, Schirmer T.** 2004. Structural basis
558 of activity and allosteric control of diguanylate cyclase. *Proc Natl Acad Sci U S A* **101**:17084-
559 17089.
- 560 15. **Paul R, Weiser S, Amiot NC, Chan C, Schirmer T, Giese B, Jenal U.** 2004. Cell cycle-
561 dependent dynamic localization of a bacterial response regulator with a novel di-guanylate
562 cyclase output domain. *Genes Dev* **18**:715-727.
- 563 16. **Holland LM, O'Donnell ST, Ryjenkov DA, Gomelsky L, Slater SR, Fey PD, Gomelsky M,**
564 **O'Gara JP.** 2008. A staphylococcal GGDEF domain protein regulates biofilm formation
565 independently of c-di-GMP. *J Bacteriol.*

- 566 17. **Hunter JL, Severin GB, Koestler BJ, Waters CM.** 2014. The *Vibrio cholerae* diguanylate
567 cyclase VCA0965 has an AGDEF active site and synthesizes cyclic di-GMP. *BMC Microbiol*
568 **14**:22.
- 569 18. **Perez-Mendoza D, Coulthurst SJ, Humphris S, Campbell E, Welch M, Toth IK, Salmond**
570 **GP.** 2011. A multi-repeat adhesin of the phytopathogen, *Pectobacterium atrosepticum*, is
571 secreted by a Type I pathway and is subject to complex regulation involving a non-canonical
572 diguanylate cyclase. *Mol Microbiol* **82**:719-733.
- 573 19. **Oliveira MC, Teixeira RD, Andrade MO, Pinheiro GM, Ramos CH, Farah CS.** 2015.
574 Cooperative substrate binding by a diguanylate cyclase. *J Mol Biol* **427**:415-432.
- 575 20. **Christen B, Christen M, Paul R, Schmid F, Folcher M, Jenoe P, Meuwly M, Jenal U.** 2006.
576 Allosteric Control of Cyclic di-GMP Signaling. *J Biol Chem* **281**:32015-32024.
- 577 21. **Dahlstrom KM, Giglio KM, Sondermann H, O'Toole GA.** 2016. The Inhibitory Site of a
578 Diguanylate Cyclase Is a Necessary Element for Interaction and Signaling with an Effector
579 Protein. *J Bacteriol* **198**:1595-1603.
- 580 22. **Yang CY, Chin KH, Chuah ML, Liang ZX, Wang AH, Chou SH.** 2011. The structure and
581 inhibition of a GGDEF diguanylate cyclase complexed with (c-di-GMP)₂ at the active site.
582 *Acta Crystallogr D Biol Crystallogr* **67**:997-1008.
- 583 23. **Rao F, Pasunooti S, Ng Y, Zhuo W, Lim L, Liu AW, Liang ZX.** 2009. Enzymatic synthesis of
584 c-di-GMP using a thermophilic diguanylate cyclase. *Anal Biochem* **389**:138-142.
- 585 24. **Ozaki S, Schalch-Moser A, Zumthor L, Manfredi P, Ebbensgaard A, Schirmer T, Jenal U.**
586 2014. Activation and polar sequestration of PopA, a c-di-GMP effector protein involved in
587 *Caulobacter crescentus* cell cycle control. *Mol Microbiol* **94**:580-594.
- 588 25. **Lee VT, Matewish JM, Kessler JL, Hyodo M, Hayakawa Y, Lory S.** 2007. A cyclic-di-GMP
589 receptor required for bacterial exopolysaccharide production. *Mol Microbiol* **65**:1474-1484.
- 590 26. **Koseoglu VK, Heiss C, Azadi P, Topchiy E, Guvener ZT, Lehmann TE, Miller KW,**
591 **Gomelsky M.** 2015. *Listeria monocytogenes* exopolysaccharide: origin, structure,
592 biosynthetic machinery and c-di-GMP-dependent regulation. *Mol Microbiol*
593 doi:10.1111/mmi.12966.
- 594 27. **Hobley L, Fung RK, Lambert C, Harris MA, Dabhi JM, King SS, Basford SM, Uchida K, Till**
595 **R, Ahmad R, Aizawa S, Gomelsky M, Sockett RE.** 2012. Discrete cyclic di-GMP-dependent
596 control of bacterial predation versus axenic growth in *Bdellovibrio bacteriovorus*. *PLoS*
597 *Pathog* **8**:e1002493.
- 598 28. **Christen M, Christen B, Folcher M, Schauerte A, Jenal U.** 2005. Identification and
599 characterization of a cyclic di-GMP-specific phosphodiesterase and its allosteric control by
600 GTP. *J Biol Chem* **280**:30829-30837.
- 601 29. **Tamayo R, Schild S, Pratt JT, Camilli A.** 2008. Role of cyclic Di-GMP during *el tor* biotype
602 *Vibrio cholerae* infection: characterization of the in vivo-induced cyclic Di-GMP
603 phosphodiesterase CdpA. *Infect Immun* **76**:1617-1627.
- 604 30. **Rao F, See RY, Zhang D, Toh DC, Ji Q, Liang ZX.** 2010. YybT is a signaling protein that
605 contains a cyclic dinucleotide phosphodiesterase domain and a GGDEF domain with ATPase
606 activity. *J Biol Chem* **285**:473-482.
- 607 31. **Hallberg ZF, Wang XC, Wright TA, Nan B, Ad O, Yeo J, Hammond MC.** 2016. Hybrid
608 promiscuous (Hypr) GGDEF enzymes produce cyclic AMP-GMP (3', 3'-cGAMP). *Proc Natl*
609 *Acad Sci U S A* **113**:1790-1795.
- 610 32. **Romling U, Galperin MY, Gomelsky M.** 2013. Cyclic di-GMP: the first 25 years of a
611 universal bacterial second messenger. *Microbiol Mol Biol Rev* **77**:1-52.
- 612 33. **Dahlstrom KM, Giglio KM, Collins AJ, Sondermann H, O'Toole GA.** 2015. Contribution of
613 Physical Interactions to Signaling Specificity between a Diguanylate Cyclase and Its Effector.
614 *MBio* **6**:e01978-01915.


- 615 34. **Lindenberg S, Klauck G, Pesavento C, Klauck E, Hengge R.** 2013. The EAL domain protein
616 YciR acts as a trigger enzyme in a c-di-GMP signalling cascade in *E. coli* biofilm control.
617 *EMBO J* **32**:2001-2014.
- 618 35. **Ryan RP, McCarthy Y, Kiely PA, O'Connor R, Farah CS, Armitage JP, Dow JM.** 2012.
619 Dynamic complex formation between HD-GYP, GGDEF and PilZ domain proteins regulates
620 motility in *Xanthomonas campestris*. *Mol Microbiol* **86**:557-567.
- 621 36. **Ryan RP, Dow JM.** 2010. Intermolecular interactions between HD-GYP and GGDEF domain
622 proteins mediate virulence-related signal transduction in *Xanthomonas campestris*.
623 *Virulence* **1**:404-408.
- 624 37. **Schmidt AJ, Ryjenkov DA, Gomelsky M.** 2005. The ubiquitous protein domain EAL is a
625 cyclic diguanylate-specific phosphodiesterase: enzymatically active and inactive EAL
626 domains. *J Bacteriol* **187**:4774-4781.
- 627 38. **Tischler AD, Camilli A.** 2004. Cyclic diguanylate (c-di-GMP) regulates *Vibrio cholerae*
628 biofilm formation. *Mol Microbiol* **53**:857-869.
- 629 39. **Tal R, Wong HC, Calhoon R, Gelfand D, Fear AL, Volman G, Mayer R, Ross P, Amikam D,**
630 **Weinhouse H, Cohen A, Sapir S, Ohana P, Benziman M.** 1998. Three *cdg* operons control
631 cellular turnover of cyclic di-GMP in *Acetobacter xylinum*: genetic organization and
632 occurrence of conserved domains in isoenzymes. *J Bacteriol* **180**:4416-4425.
- 633 40. **Tchigvintsev A, Xu X, Singer A, Chang C, Brown G, Proudfoot M, Cui H, Flick R,**
634 **Anderson WF, Joachimiak A, Galperin MY, Savchenko A, Yakunin AF.** 2010. Structural
635 insight into the mechanism of c-di-GMP hydrolysis by EAL domain phosphodiesterases. *J Mol*
636 *Biol* **402**:524-538.
- 637 41. **Sundriyal A, Massa C, Samoray D, Zehender F, Sharpe T, Jenal U, Schirmer T.** 2014.
638 Inherent regulation of EAL domain-catalyzed hydrolysis of second messenger cyclic di-GMP.
639 *J Biol Chem* **289**:6978-6990.
- 640 42. **Rao F, Qi Y, Chong HS, Kotaka M, Li B, Li J, Lescar J, Tang K, Liang ZX.** 2009. The
641 functional role of a conserved loop in EAL domain-based cyclic di-GMP-specific
642 phosphodiesterase. *J Bacteriol* **191**:4722-4731.
- 643 43. **Rao F, Yang Y, Qi Y, Liang ZX.** 2008. Catalytic mechanism of cyclic di-GMP-specific
644 phosphodiesterase: a study of the EAL domain-containing RocR from *Pseudomonas*
645 *aeruginosa*. *J Bacteriol* **190**:3622-3631.
- 646 44. **Barends TR, Hartmann E, Griese JJ, Beitlich T, Kirienko NV, Ryjenkov DA, Reinstein J,**
647 **Shoeman RL, Gomelsky M, Schlichting I.** 2009. Structure and mechanism of a bacterial
648 light-regulated cyclic nucleotide phosphodiesterase. *Nature* **459**:1015-1018.
- 649 45. **Toth-Petroczy A, Tawfik DS.** 2014. The robustness and innovability of protein folds. *Curr*
650 *Opin Struct Biol* **26**:131-138.
- 651 46. **Navarro MV, Newell PD, Krasteva PV, Chatterjee D, Madden DR, O'Toole GA,**
652 **Sondermann H.** 2011. Structural basis for c-di-GMP-mediated inside-out signaling
653 controlling periplasmic proteolysis. *PLoS Biol* **9**:e1000588.
- 654 47. **Chatterjee D, Cooley RB, Boyd CD, Mehl RA, O'Toole GA, Sondermann H.** 2014.
655 Mechanistic insight into the conserved allosteric regulation of periplasmic proteolysis by the
656 signaling molecule cyclic-di-GMP. *Elife* **3**:e03650.
- 657 48. **Chin KH, Kuo WT, Yu YJ, Liao YT, Yang MT, Chou SH.** 2012. Structural polymorphism of c-
658 di-GMP bound to an EAL domain and in complex with a type II PilZ-domain protein. *Acta*
659 *Crystallogr D Biol Crystallogr* **68**:1380-1392.
- 660 49. **Guzzo CR, Dunger G, Salinas RK, Farah CS.** 2013. Structure of the PilZ-FimXEAL-c-di-GMP
661 Complex Responsible for the Regulation of Bacterial Type IV Pilus Biogenesis. *J Mol Biol*
662 **425**:2174-2197.

- 663 50. **Chou SH, Galperin MY.** 2016. Diversity of Cyclic Di-GMP-Binding Proteins and Mechanisms. *J Bacteriol* **198**:32-46.
- 664
- 665 51. **Li B, Li N, Wang F, Guo L, Huang Y, Liu X, Wei T, Zhu D, Liu C, Pan H, Xu S, Wang HW, Gu**
- 666 **L.** 2012. Structural insight of a concentration-dependent mechanism by which YdiV inhibits
- 667 *Escherichia coli* flagellum biogenesis and motility. *Nucleic Acids Res* **40**:11073-11085.
- 668 52. **Ahmad I, Wigren E, Le Guyon S, Vekkei S, Blanka A, El Mouali Y, Anwar N, Chuah ML,**
- 669 **Lunsdorf H, Frank R, Rhen M, Liang ZX, Lindqvist Y, Romling U.** 2013. The EAL-like
- 670 protein STM1697 regulates virulence phenotypes, motility and biofilm formation in
- 671 *Salmonella typhimurium*. *Mol Microbiol* **90**:1216-1232.
- 672 53. **Wada T, Morizane T, Abo T, Tominaga A, Inoue-Tanaka K, Kutsukake K.** 2011. EAL
- 673 domain protein YdiV acts as an anti-FlhD4C2 factor responsible for nutritional control of the
- 674 flagellar regulon in *Salmonella enterica* Serovar Typhimurium. *J Bacteriol* **193**:1600-1611.
- 675 54. **Takaya A, Erhardt M, Karata K, Winterberg K, Yamamoto T, Hughes KT.** 2012. YdiV: a
- 676 dual function protein that targets FlhDC for ClpXP-dependent degradation by promoting
- 677 release of DNA-bound FlhDC complex. *Mol Microbiol* **83**:1268-1284.
- 678 55. **Spurbeck RR, Alteri CJ, Himpel SD, Mobley HL.** 2013. The multifunctional protein YdiV
- 679 represses P fimbria-mediated adherence in uropathogenic *Escherichia coli*. *J Bacteriol*
- 680 **195**:3156-3164.
- 681 56. **Bharati BK, Sharma IM, Kasetty S, Kumar M, Mukherjee R, Chatterji D.** 2012. A full-
- 682 length bifunctional protein involved in c-di-GMP turnover is required for long-term survival
- 683 under nutrient starvation in *Mycobacterium smegmatis*. *Microbiology* **158**:1415-1427.
- 684 57. **Feirer N, Xu J, Allen KD, Koestler BJ, Bruger EL, Waters CM, White RH, Fuqua C.** 2015. A
- 685 Pterin-Dependent Signaling Pathway Regulates a Dual-Function Diguanylate Cyclase-
- 686 Phosphodiesterase Controlling Surface Attachment in *Agrobacterium tumefaciens*. *MBio*
- 687 **6**:e00156.
- 688 58. **Huber B, Riedel K, Kothe M, Givskov M, Molin S, Eberl L.** 2002. Genetic analysis of
- 689 functions involved in the late stages of biofilm development in *Burkholderia cepacia* H111.
- 690 *Mol Microbiol* **46**:411-426.
- 691 59. **Qi Y, Rao F, Luo Z, Liang ZX.** 2009. A flavin cofactor-binding PAS domain regulates c-di-
- 692 GMP synthesis in AxhDGC2 from *Acetobacter xylinum*. *Biochemistry* **48**:10275-10285.
- 693 60. **Lahiri T, Luan B, Raleigh DP, Boon EM.** 2014. A structural basis for the regulation of an H-
- 694 NOX-associated cyclic-di-GMP synthase/phosphodiesterase enzyme by nitric oxide-bound
- 695 H-NOX. *Biochemistry* **53**:2126-2135.
- 696 61. **Tarutina M, Ryjenkov DA, Gomelsky M.** 2006. An unorthodox bacteriophytochrome from
- 697 *Rhodobacter sphaeroides* involved in turnover of the second messenger c-di-GMP. *J Biol*
- 698 *Chem* **281**:34751-34758.
- 699 62. **Ross P, Weinhouse, H., Aloni, Y., Michaeli, D., Weinberger-Ohana, P., Mayer, R., Braun,**
- 700 **S., de Vroom, E., van der Marel, G.A., van Boom, J.H., Benziman, M.** 1987. Regulation of
- 701 cellulose synthesis in *Acetobacter xylinum* by cyclic diguanylic acid. *Nature* **325**:279-281.
- 702 63. **Goldman SR, Sharp JS, Vvedenskaya IO, Livny J, Dove SL, Nickels BE.** 2011. NanoRNAs
- 703 prime transcription initiation in vivo. *Mol Cell* **42**:817-825.
- 704 64. **Orr MW, Donaldson GP, Severin GB, Wang J, Sintim HO, Waters CM, Lee VT.** 2015.
- 705 Oligoribonuclease is the primary degradative enzyme for pGpG in *Pseudomonas aeruginosa*
- 706 that is required for cyclic-di-GMP turnover. *Proc Natl Acad Sci U S A* **112**:E5048-5057.
- 707 65. **Cohen D, Mechold U, Nevenzal H, Yarmiyahu Y, Randall TE, Bay DC, Rich JD, Parsek MR,**
- 708 **Kaever V, Harrison JJ, Banin E.** 2015. Oligoribonuclease is a central feature of cyclic
- 709 diguanylate signaling in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A* **112**:11359-
- 710 11364.

- 711 66. **Ryan RP, Fouhy Y, Lucey JF, Crossman LC, Spiro S, He YW, Zhang LH, Heeb S, Camara M,**
712 **Williams P, Dow JM.** 2006. Cell-cell signaling in *Xanthomonas campestris* involves an HD-
713 GYP domain protein that functions in cyclic di-GMP turnover. *Proc Natl Acad Sci U S A*
714 **103**:6712-6717.
- 715 67. **Slater H, Alvarez-Morales A, Barber CE, Daniels MJ, Dow JM.** 2000. A two-component
716 system involving an HD-GYP domain protein links cell-cell signalling to pathogenicity gene
717 expression in *Xanthomonas campestris*. *Mol Microbiol* **38**:986-1003.
- 718 68. **Ryan RP.** 2013. Cyclic di-GMP signalling and the regulation of bacterial virulence.
719 *Microbiology* **159**:1286-1297.
- 720 69. **Zhang Y, Wei C, Jiang W, Wang L, Li C, Wang Y, Dow JM, Sun W.** 2013. The HD-GYP
721 domain protein RpfG of *Xanthomonas oryzae* pv. *oryzicola* regulates synthesis of
722 extracellular polysaccharides that contribute to biofilm formation and virulence on rice.
723 *PLoS One* **8**:e59428.
- 724 70. **Ryan RP, McCarthy Y, Andrade M, Farah CS, Armitage JP, Dow JM.** 2010. Cell-cell signal-
725 dependent dynamic interactions between HD-GYP and GGDEF domain proteins mediate
726 virulence in *Xanthomonas campestris*. *Proc Natl Acad Sci U S A* **107**:5989-5994.
- 727 71. **Bellini D, Caly DL, McCarthy Y, Bumann M, An SQ, Dow JM, Ryan RP, Walsh MA.** 2014.
728 Crystal structure of an HD-GYP domain cyclic-di-GMP phosphodiesterase reveals an enzyme
729 with a novel trinuclear catalytic iron centre. *Mol Microbiol* **91**:26-38.
- 730 72. **Lovering AL, Capeness MJ, Lambert C, Hobley L, Sockett RE.** 2011. The structure of an
731 unconventional HD-GYP protein from *Bdellovibrio* reveals the roles of conserved residues in
732 this class of cyclic-di-GMP phosphodiesterases. *MBio* **2**.
- 733 73. **Rinaldo S, Paiardini A, Stelitano V, Brunotti P, Cervoni L, Fernicola S, Protano C, Vitali**
734 **M, Cutruzzola F, Giardina G.** 2015. Structural basis of functional diversification of the HD-
735 GYP domain revealed by the *Pseudomonas aeruginosa* PA4781 protein, which displays an
736 unselective bimetallic binding site. *J Bacteriol* **197**:1525-1535.
- 737 74. **Miner KD, Kurtz DM, Jr.** 2016. Active Site Metal Occupancy and Cyclic Di-GMP
738 Phosphodiesterase Activity of *Thermotoga maritima* HD-GYP. *Biochemistry* **55**:970-979.
- 739 75. **Sultan SZ, Pitzer JE, Boquoi T, Hobbs G, Miller MR, Motaleb MA.** 2011. Analysis of the
740 HD-GYP domain cyclic dimeric GMP phosphodiesterase reveals a role in motility and the
741 enzootic life cycle of *Borrelia burgdorferi*. *Infect Immun* **79**:3273-3283.
- 742 76. **Miner KD, Klose KE, Kurtz DM, Jr.** 2013. An HD-GYP cyclic di-guanosine monophosphate
743 phosphodiesterase with a non-heme diiron-carboxylate active site. *Biochemistry* **52**:5329-
744 5331.
- 745 77. **Plate L, Marletta MA.** 2012. Nitric oxide modulates bacterial biofilm formation through a
746 multicomponent cyclic-di-GMP signaling network. *Mol Cell* **46**:449-460.
- 747 78. **Ryan RP, Lucey J, O'Donovan K, McCarthy Y, Yang L, Tolker-Nielsen T, Dow JM.** 2009.
748 HD-GYP domain proteins regulate biofilm formation and virulence in *Pseudomonas*
749 *aeruginosa*. *Environ Microbiol* **11**:1126-1136.
- 750 79. **Wigren E, Liang ZX, Romling U.** 2014. Finally! The structural secrets of a HD-GYP
751 phosphodiesterase revealed. *Mol Microbiol* **91**:1-5.
- 752 80. **Navarro MV, De N, Bae N, Wang Q, Sondermann H.** 2009. Structural analysis of the
753 GGDEF-EAL domain-containing c-di-GMP receptor FimX. *Structure* **17**:1104-1116.
- 754 81. **Stelitano V, Giardina G, Paiardini A, Castiglione N, Cutruzzola F, Rinaldo S.** 2013. C-di-
755 GMP hydrolysis by *Pseudomonas aeruginosa* HD-GYP phosphodiesterases: analysis of the
756 reaction mechanism and novel roles for pGpG. *PLoS One* **8**:e74920.
- 757 82. **Brown PM, Caradoc-Davies TT, Dickson JM, Cooper GJ, Loomes KM, Baker EN.** 2006.
758 Crystal structure of a substrate complex of myo-inositol oxygenase, a di-iron oxygenase with
759 a key role in inositol metabolism. *Proc Natl Acad Sci U S A* **103**:15032-15037.

- 760 83. **McKee RW, Kariisa A, Mudrak B, Whitaker C, Tamayo R.** 2014. A systematic analysis of
761 the in vitro and in vivo functions of the HD-GYP domain proteins of *Vibrio cholerae*. *BMC*
762 *Microbiol* **14**:272.
- 763 84. **Rajeev L, Luning EG, Altenburg S, Zane GM, Baidoo EE, Catena M, Keasling JD, Wall JD,**
764 **Fields MW, Mukhopadhyay A.** 2014. Identification of a cyclic-di-GMP-modulating response
765 regulator that impacts biofilm formation in a model sulfate reducing bacterium. *Front*
766 *Microbiol* **5**:382.
- 767 85. **Andrade MO, Alegria MC, Guzzo CR, Docena C, Rosa MC, Ramos CH, Farah CS.** 2006. The
768 HD-GYP domain of RpfG mediates a direct linkage between the Rpf quorum-sensing pathway
769 and a subset of diguanylate cyclase proteins in the phytopathogen *Xanthomonas axonopodis*
770 *pv citri*. *Mol Microbiol* **62**:537-551.
- 771 86. **Davies BW, Bogard RW, Young TS, Mekalanos JJ.** 2012. Coordinated regulation of
772 accessory genetic elements produces cyclic di-nucleotides for *V. cholerae* virulence. *Cell*
773 **149**:358-370.
- 774 87. **Gao J, Tao J, Liang W, Zhao M, Du X, Cui S, Duan H, Kan B, Su X, Jiang Z.** 2015.
775 Identification and characterization of phosphodiesterases that specifically degrade 3'3'-
776 cyclic GMP-AMP. *Cell Res* **25**:539-550.
- 777 88. **Luo Y, Helmann JD.** 2012. Analysis of the role of *Bacillus subtilis* sigma(M) in beta-lactam
778 resistance reveals an essential role for c-di-AMP in peptidoglycan homeostasis. *Mol*
779 *Microbiol* **83**:623-639.
- 780 89. **Corrigan RM, Abbott JC, Burhenne H, Kaever V, Grundling A.** 2011. c-di-AMP is a new
781 second messenger in *Staphylococcus aureus* with a role in controlling cell size and envelope
782 stress. *PLoS Pathog* **7**:e1002217.
- 783 90. **Bai Y, Yang J, Eisele LE, Underwood AJ, Koestler BJ, Waters CM, Metzger DW, Bai G.**
784 2013. Two DHH subfamily 1 proteins in *Streptococcus pneumoniae* possess cyclic di-AMP
785 phosphodiesterase activity and affect bacterial growth and virulence. *J Bacteriol* **195**:5123-
786 5132.
- 787 91. **Fang M, Zeisberg WM, Condon C, Ogryzko V, Danchin A, Mechold U.** 2009. Degradation
788 of nanoRNA is performed by multiple redundant RNases in *Bacillus subtilis*. *Nucleic Acids*
789 *Res* **37**:5114-5125.
- 790 92. **Mechold U, Fang G, Ngo S, Ogryzko V, Danchin A.** 2007. YtqI from *Bacillus subtilis* has
791 both oligoribonuclease and pAp-phosphatase activity. *Nucleic Acids Res* **35**:4552-4561.
- 792 93. **Huynh TN, Luo S, Pensinger D, Sauer JD, Tong L, Woodward JJ.** 2015. An HD-domain
793 phosphodiesterase mediates cooperative hydrolysis of c-di-AMP to affect bacterial growth
794 and virulence. *Proc Natl Acad Sci U S A* **112**:E747-756.
- 795 94. **He Q, Wang F, Liu S, Zhu D, Cong H, Gao F, Li B, Wang H, Lin Z, Liao J, Gu L.** 2016.
796 Structural and Biochemical Insight into the Mechanism of Rv2837c from *Mycobacterium*
797 *tuberculosis* as a c-di-NMP Phosphodiesterase. *J Biol Chem* **291**:3668-3681.
- 798 95. **Ryu MH, Moskvina OV, Siltberg-Liberles J, Gomelsky M.** 2010. Natural and engineered
799 photoactivated nucleotidyl cyclases for optogenetic applications. *J Biol Chem* **285**:41501-
800 41508.
- 801 96. **Tucker CL, Hurley JH, Miller TR, Hurley JB.** 1998. Two amino acid substitutions convert a
802 guanylyl cyclase, RetGC-1, into an adenylyl cyclase. *Proc Natl Acad Sci U S A* **95**:5993-5997.
- 803 97. **Belyy A, Raoux-Barbot D, Saveanu C, Namane A, Ogryzko V, Worpenberg L, David V,**
804 **Henriot V, Fellous S, Merrifield C, Assayag E, Ladant D, Renault L, Mechold U.** 2016.
805 Actin activates *Pseudomonas aeruginosa* ExoY nucleotidyl cyclase toxin and ExoY-like
806 effector domains from MARTX toxins. *Nat Commun* **7**:13582.

- 807 98. **Kranzusch PJ, Lee AS, Wilson SC, Solovykh MS, Vance RE, Berger JM, Doudna JA.** 2014.
808 Structure-guided reprogramming of human cGAS dinucleotide linkage specificity. *Cell*
809 **158**:1011-1021.
- 810 99. **Kranzusch PJ, Wilson SC, Lee AS, Berger JM, Doudna JA, Vance RE.** 2015. Ancient Origin
811 of cGAS-STING Reveals Mechanism of Universal 2',3' cGAMP Signaling. *Mol Cell* **59**:891-903.
- 812 100. **Lopez-Villamizar I, Cabezas A, Pinto RM, Canales J, Ribeiro JM, Cameselle JC, Costas MJ.**
813 2016. The Characterization of *Escherichia coli* CpdB as a Recombinant Protein Reveals that,
814 besides Having the Expected 3'-Nucleotidase and 2',3'-Cyclic Mononucleotide
815 Phosphodiesterase Activities, It Is Also Active as Cyclic Dinucleotide Phosphodiesterase.
816 *PLoS One* **11**:e0157308.
817



Class I

PleD_CAUCR
 WspT_PSEAE
 STM4551_SALTY
 YdeH_ECOLI
 AdrA_SALTY
 PA4332_PSEAE
 DgcB_CAUCR
 CD1420_Cdif
 Pf101_4666
 XC0420_XANC8
 VCA0965_VIBCH
 ECA3270_PECAS
 GSU1658_GEOSL
 MXAN_2643

292 DQLTGLHNRRYM
 DGLTGLSNRRHF
 DPLTGLYNRRGL
 DVLTGLPGRRVL
 DGMTGVYNNRRHW
 DELTGLFNRRHF
 DGLTNLANRKAF
 DPLTGAYNRKYL
 DALTGVANRRML
 DQLTGALNRRGF
 DPLTGLANRWSF
 DSLTSLANGLTF
 DELTGLFNRYL
 DEHTGCYNARHL

327 DIDFFKLNDFFGHDIGDEVL
 DVDYFKSYNDFFGHVAGDEAL
 DIDHFKAYNDHYGHMMGDQAL
 DIDRFKLYNDTYGHLIGDVVL
 DTDHFKSINDTWGHDVGEAL
 DLDHFKRINDRHGHAAGDRVLL
 DIDHFKGFNDTWGHQTGDQVL
 DLDNFKMINDYEGHNVGDKIL
 DADHFKAFNDRHGHAAGDQAL
 DLDHFKRINDTWGHAGGDAAL
 DIDNFKRINDSYGHVGDQVL
 DLDKFKQINDSFGHAVGDLLEL
 DMDHFKGVNDTHGHVFGSQQVL
 DLDHFKSINDTHGHVFGSATL

359 RAID
 RSSD
 RSRD
 RDYD
 RGS
 RDS
 APPR
 NSTS
 RPAD
 RTTD
 RNKD
 RDS
 REVD
 QNLD

370 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF
 RYGGEEF

TISIG
 TVSIG
 TNVTV
 TVTAG
 RISVG
 SLSVG
 TVSSG
 SFSYG
 TVSIG
 SFSYG
 TVSIG
 TVSIG
 TVSIG
 TASIG
 TASVG

434 ADEGVYQAKASGRNA
 ADQALYQAKNNGRNQ
 ADKALYEAHLGRNH
 ADRAMYEGKQTGRNR
 ADQALYKAKNAGRNR
 ADQALYRAKRGGRNR
 ADAALYASAKRGGRNR
 ADKAMYKAKNKKK
 ADKALYQAKEGGRNR
 ADRAMYDSKAAGKNR
 ADKAMYAAKNGKINQ
 ADSAMYQAKAMGRSQ
 ADKAMYRGKEEGKNR
 ADFAMYAAKARGRDA

Class II

YciR_SALTY
 DGC1_KOMXY
 Y1354_MYCTU_Rv1354c

DTVVTGLPNRRAI
 DPLTGLFNRRGF
 DDLTGLHNRRAL

DLNFKKINDAYGHMFGDQLL
 DLDGFKQINDIHGHAGDVVLL
 DLDRLKAINDYLGHAAAGDQFL

LEED
 HPED
 RIGD

RLGGDEF
 RLGGDEF
 RLGGDEF

GCAIG
 SGSIG
 TVSIG

ADTAMYNKAKEGGRGQ
 ADIALYAAKRAAGGHQ
 ADQAALAAKHAGGDS

Class III

SE_0528_STAES
 PopA_CAUCR
 lmo0531_LISMO
 BifA_PSEAE
 STM2503_SALTY
 CsrD_ECOLI
 CC3396_CAUCR
 CdpA_VIBCH
 YybT_BSUB

DYLTGLGNVKKFF
 DAATGLFTRLDLF
 DQETLLKNIVSFF
 DFLTGLPNRQLL
 DPVVHLPNLRAL
 DVKTGLNRRLLFF
 CDLTGLLDRRSF
 SLTASYRDRR
 ERFIAVLNEHLL


DIDGFKDVNDHYSHQSDAVL
 RVADKPEVWARQNGWLDRLAL
 KVRHWRELKRFQSEDEMRLAL
 GLDDFKGINEQYTYQLGDQLL
 GKNYGVMLRIQYKQKLSHWIT
 RLPDFNMLSDTWGHSQVEEQF
 DLDRLRRLNEALGHERADLVLL
 KVTNFNQINEKYGYVPGDKLL
 TLSYGVGASVSSLKELGDLAQ

PNQF
 RVED
 RTSD
 RLGS
 SGHD
 RYPG
 PAQS
 QKLA
 QVAI

RNGGEEF
 RLATEVF
 LLDKDEA
 RLGGDQF
 RLNTEAH
 RYHRSDF
 RIGEEDEF
 AIGVGEW
 FYGGKTN

SIGVG
 EFDIG
 ELRIG
 RATIG
 YLLG
 MIHIG
 TISIG
 SISLG
 GAAIG

ADDMVHVAKSEGRNK
 ERAAAAALKREAG
 ADLATKELEYDV
 AEQTMTLAKTRSRNR
 QRRGAMHLQRDLKGR
 AESATRNAGLQGGNS
 AELAVEAANAAGRGG
 IEARRYAFNNHHFC
 NQIGSSVQRLLIGEIK



Class I

RocR_Paer	160	175	190	197	232	265	282	316	321	349	372
	YQP	EVLAR	PS-HF	ME	FN	EITE	LVRLRIMGCGLAMDDFGAGYSSLDL	KLD	FV	LVVEGVES	QGYL
VieA_Vchol	YQP	EALVR	PSIEQ	HE	VN	EMTE	LARLRMYGVGLSIDDFGTGYASLGQ	KID	FV	CVVEGVEN	QGYI
Tbd1265	YQP	EALVR	PAAED	IV	VN	EITE	LDALRARGVRLALDDFGTGYSSLSY	KID	FV	VVAEGIET	QGNL
Blrp1_Kpneu	LQA	EALIR	PVEMF	AE	IN	EVTE	LKALRVAGMKLAIDDFGAGYSSLSL	KVD	EV	VVAEGVET	QGFL
Y1354_MYCTU_Rv1354c	YQP	EALVR	PG-CF	AE	IN	EITE	LARLKEVGVHIAIDDFGTGYSAISL	KID	FV	VVAEGVET	QGFL
DosP_Ecoli	YQP	EALAR	PS-RF	AE	VN	EITE	IQILRDMGVGLSVDDFGTGFSGLSR	KID	FV	VVAEGVET	QGYF
MorA_Paer	YQP	EALLR	PS-EF	LE	VN	ELTE	LSGLKRLGLAIAVDDFGTGYSSLNY	KID	FV	VIAEGVES	QGYL
Atu3495_Agfab	YQP	EALLR	PS-VF	AE	VN	EITE	LSRLRIMGCGLAMDDFGTGYSSLAN	KID	FL	TIAEGIET	QGYL
PDEA3_Koxyl	YQP	EALSR	PS-RF	AE	VN	EITE	LQSIRNIGCGLSMDDFGTGYSSLSR	KID	FI	VVTEGVET	QGYL
Ip10329LePne	YQP	EALIR	PL-DF	AE	CN	EITE	LKKLKSLGLVLIILDDFGTGNSSLNL	KID	FI	IIAEGVET	QGFL
YciR_Salty	YQP	EALVR	PL-EF	AE	VN	ELTE	LQQFSQLGAQIHLDDFGTGYSSLSQ	KLD	FV	VIAEGVEN	QGFL
cc3396	FQP	EALAR	PD-EF	IE	VN	EVTE	LKTLRDAGAGLALDDFGTGFSSLSY	KID	FV	VVAEGVEN	QGFG
BifA_Paer	YQP	EALLR	PD-HF	AE	VN	EVTE	LLSLRRAGALIAIDDFGTGYSSLSY	KID	FV	VIAEGVET	QGYL
HmsP_Ypest	LQP	EALLR	PS-GF	AE	VN	EITE	LRELQGLGLLIAIDDFGIGYSSLR	KLD	FV	VMAEGVET	QGFL

Class II**Class IIa**

YhjH	YQP	ELLTV	PDRYF	AV	VN	ELVE	FASMCEFGPL-WLDDFGTGMANFSA	KVA	FV	VIVEGVET	QGYFL
YE2225_Yente	CEP	ELLSR	YTERF	LN	IN	EIME	LSKLSKRY-S-LWLDDFGSGNAHLAA	KID	FY	VVVEGVET	QGYL

Class IIb




Ykul_Bsub	YQA	EVLGR	GP-FF	PE	IF	EITE	LAYYRTYGIKIAVDNIGKESNLDR	KID	AL	LLYEDIEA	QGYI
DGC2_Komyxl	YQP	EALLR	AE-DF	FT	IN	EVTE	LRELARAGFRIALDNFGKITVLNH	KID	MV	VVVEGVEN	QGFF



Class III**Class IIIa**

LapD_Psfluor	FQP	KVLSR	PAGRF	LE	LN	EIGE	TRRLRELGFSLSLQRFGGRFSMIGN	KID	YI	LIAERVET	QQQL
FimX_Paer	FQP	EVLRL	PA-EF	KE	VH	QISE	LTQGLATLHCQAASQFGGSLNPFN	KID	FV	PIVPPVES	QGYLL
PXO_00403	YQP	QAFRL	PN-AF	AE	VR	QTPE	LSAVSAMGCKVGLQFGSGLDFSQL	KLD	IT	TMAEFVAD	QGDF
Lpg1057_Lpneu	YQP	EVLRL	PD-EF	AE	IN	ELEI	LSTLRNMGVKLAEDNFGSGYSFLSH	KLK	LI	VVVGIVET	QGYI

Class IIIb

YcgF_Ecoli	FHP	EAIVQ	VGQRK	EI	IN	EFTE	IKSLKAAGISVAIDHFGAGFAGLLL	KIS	LI	VSAMGVAT	QGDL
YE1324	CEP	ELLSR	DVENF	LD	IN	EIME	LRDLAER-YPLWLDLGGSGSTLNA	KID	FF	VIVVGVEN	QGYL
STM1697	AEP	EITTH	P--EF	WD	FC	ELQV	IHALHKQPNPLWGLDVGVNATAAP	KLD	FF	IIVVGGQEN	QGTL
STM1344	FLP	EIIAT	P-TEL	RL	WL	ELAI	TLANLAMHFPPLMLANFGAGEASTKA	MLD	FI	LMIAGIET	QGGL
ToxR_Paer	FAH	KLSLR	LSAFL	AE	FI	ELCL	LARLRDSGVRIALHPQRIDTDARQC	GLD	LL	MLCLNVEN	HGRH
CsrD_Ecoli	YQK	ELMCR	SA-EY	VL	IQ	ELAE	LRLVNALGVRVAVNQAGLTLVSTSW	KLH	LV	VYATGVRS	QGDF

A**B****C**



	S-helix	Helix 1	Loop1/2
<i>PmGH</i>	LKKAHEDVIYRLSH--ATKFKD PETQNH IIRVGLYAEILAREA-----GLDE-EDVE		
Bd1817	--NFIMSNAQALSAVMNIENT DKTISHH GVTVSTLSIALAQKL-----GITDPKKTQ		
BB0374	-----IFIKYFR--IPKLSANY HIH SVNTAILTVALGNEM-----GLNN-YKTV		
PA4781	LQQQLQDAVIEALAT--LGDLR DNPRSRH LPRIERYVRLLAEHLAAQRAFADLTP-EAVD		
VCA0681	VE-EIMSIAMLMAN--VVDAKSQ FTFQH SQKVAELCQHLAKEL-----GLNV-EMQK		
PA4108	--PNALLSLVRLKT--S---- DEYTYMH SVAVCALMIALARQL-----ELPD-PLVR		
RpfG	VEERERETLSRLAR--AIEYRD GGTSA FLERMESHVAGLVAEQL-----GLSE-EEVR		

	Helix 2	Helix E	Loop3/4
<i>PmGH</i>	LVKLAAP MHD IG KV GIPDRVLLK PGKLN DEEWEIMK KHTI YGYEILKGGD-----SRL		
Bd1817	LLTLGALL HDY GHHSPLNLN QPLDS MPEDLALWKK HP IEGAQKVQDKK-----HFD		
BB0374	ELCSIAL LHK IGFLFIPSKI SEK EALTEEELEI IKKYP IISYKIASTSN-----LS		
PA4781	LLSKSALL HD IG KV AVPDRVLLN PGQLD ADT-ALL QGH TRAGRDALASAERRLGQPSGFL		
VCA0681	ALYLTGL VHD IG KL LHTPEEIL HPGKLN ESEYL CIQRH STDSRYTLQMVF-----GQ		
PA4108	EAGLAGLL HD IG KM AVPDPILNK PGKLT DPEFGLVRR HP QNGARMLLDCR-----Q-VS		
RpfG	IIEMAAP LHDMG KIAIPDSVLLK PGKLT EDEMNVMKR HP RIGYELLSGSQ-----NRFI		

	Helix 4	GYP loop	Helix 5
<i>PmGH</i>	QIAADIAIE HH ERWDGT GYP FGKKGEEIS IYGR MTSIS DV FDALTS DRPYK KAWDMDRTV		
Bd1817	QTVINIIG QHE ETINGT G-PKGL REKMDPLAVLVSSANAMDRLITFEGVPKAEAAK---		
BB0374	RSICLTL LTK ENLDGT GYP KGLTSENISIESNI IGAAS AYS AII LDKAY KSF NSGASI		
PA4781	RFARQIAYS HH ERWDGR GFPE GLAGERIPLAARIVAL ADRY DELTSRHAYR PPLA HAEAV		
VCA0681	SVVCEWAGN HH ERLDGS GYP RGLQGA AIDL PSRI IAIAD VFQALT QARPY RGSMSLNEVM		
PA4108	ALVVVDVCL HHH ERIDGT GYP FGLAQEQISLLARMGAV CDVY DAITSDR DPYK KGWNAAEAI		
RpfG	QVGALIALR HH ERYDGS GYP DGLVGEA IPLE ARIVAV ADV FDALLSAR DPYK EAWTMDAAL		

	Helix 6
<i>PmGH</i>	RFFKE-QKGKHF--DP
Bd1817	KLMI D -HVGKHPLQHI
BB0374	IELIK-DADKKF--DK
PA4781	LLIQA-GAGSEF--DP
VCA0681	NIMRHEVSCGRL--DS
PA4108	RRMAE-WN-GHF--DP
RpfG	AYLYA-QRGRLF--DP